These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 25874733

  • 21. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J.
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [Abstract] [Full Text] [Related]

  • 22. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA.
    Future Oncol; 2015 Jun; 11(9):1429-35. PubMed ID: 25952787
    [Abstract] [Full Text] [Related]

  • 23. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
    Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A.
    Oncotarget; 2016 Nov 15; 7(46):76118-76124. PubMed ID: 27764798
    [Abstract] [Full Text] [Related]

  • 24. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA, Keating GM.
    Am J Clin Dermatol; 2013 Feb 15; 14(1):61-4. PubMed ID: 23329081
    [Abstract] [Full Text] [Related]

  • 25. Vismodegib in the treatment of advanced BCC.
    O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM.
    Ir Med J; 2014 Feb 15; 107(7):215-6. PubMed ID: 25226719
    [Abstract] [Full Text] [Related]

  • 26. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
    Barker CA, Dufault S, Arron ST, Ho AL, Algazi AP, Dunn LA, Humphries AA, Hultman C, Lian M, Knott PD, Yom SS.
    J Clin Oncol; 2024 Jul 01; 42(19):2327-2335. PubMed ID: 38630954
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma.
    Reinders MG, Brinkhuizen T, Soetekouw PM, Kelleners-Smeets NW, Hamid MA, Mosterd K.
    Acta Derm Venereol; 2015 May 01; 95(5):618-9. PubMed ID: 25425396
    [No Abstract] [Full Text] [Related]

  • 29. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
    Tauber G, Pavlovsky L, Fenig E, Hodak E.
    J Am Acad Dermatol; 2015 Nov 01; 73(5):799-801. PubMed ID: 26320385
    [Abstract] [Full Text] [Related]

  • 30. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
    Lucero OM, Fitzmaurice S, Thompson C, Leitenberge J.
    Dermatol Online J; 2018 Feb 15; 24(2):. PubMed ID: 29630158
    [Abstract] [Full Text] [Related]

  • 31. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE, Lim SW, Chang AL, Kelly JW.
    Australas J Dermatol; 2014 Aug 15; 55(3):218-21. PubMed ID: 25117162
    [Abstract] [Full Text] [Related]

  • 32. Potential Synergy of Radiation Therapy With Vismodegib for Basal Cell Carcinoma.
    Strasswimmer JM.
    JAMA Dermatol; 2015 Sep 15; 151(9):925-6. PubMed ID: 25874820
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
    Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, Chren MM, Arron ST.
    J Am Acad Dermatol; 2017 Oct 15; 77(4):713-718. PubMed ID: 28780365
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
    Dessinioti C, Plaka M, Dimitrakopoulou A, Stratigos AJ.
    J Eur Acad Dermatol Venereol; 2019 May 15; 33(5):e187-e188. PubMed ID: 30653740
    [No Abstract] [Full Text] [Related]

  • 39. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
    Cozzani R, Del Aguila R, Carrizo M, Sanchez S, Gonzalez A, ML29740 Investigators.
    Int J Dermatol; 2020 May 15; 59(5):627-632. PubMed ID: 32034775
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
    Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A.
    Orphanet J Rare Dis; 2016 Sep 01; 11(1):120. PubMed ID: 27581207
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.